The quote "It was the best of times, it was the worst of times," from the opening of A Tale of Two Cities by Charles Dickens is certainly appropriate for the ups and downs that the biopharma sector has experienced during 2018, particularly in the public domain where significant equity gains in the first half of the year were erased in the wake of extremely turbulent general markets that saw investors head for the sidelines. Read More
More than a third of biopharma drugs issued complete response letters (CRLs) by the FDA in 2016 later received full approval, within three to 21 months. While some investors perceive the dreaded CRL as a death sentence, as evidenced by their quick stock sell-offs, BioWorld data indicate it is sometimes merely a hiccup corrected in time. Read More
